#Morphosys #mixed #study #results #blood #cancer #drug
The German company MorphoSys announced that its experimental blood cancer drug met its primary target in a Phase 3 trial. The drug candidate, pelabresib, was tested in combination with Jakafi in patients with a rare blood cancer called myelofibrosis. The trial showed that 66% of patients saw at least a 35% reduction in spleen volume after 24 weeks, compared to 35% on a placebo regimen. Although the drug combination succeeded in reducing spleen volume, it failed to address patient symptoms. As a result, the company’s stock fell in early Tuesday trading. Myelofibrosis causes low blood cell counts and enlarged spleens, making reduced spleen volume a primary efficacy goal in clinical trials.